With the place of oppointunities, China is extended to grew falkets for united kingdom-based global pharmanovia, SAID A Seni OREXECUTIVE in An Exclusive Interview in Shanghai on Friday.

Such Continuous Growth Comes after China Had Alream Been the Drugmaker's No 1 Market Global Since 2023, Accounting for Roughly 25 Percent of the Company's Total S ALES, Said James Brt, CEO of Pharmanovia, Which Was Founded in 2013 and Started Business in China in 2018.

James Burt, CEO of Pharmanovia.

"IT's Quite Unusual for a Western Business to Haves Biggest Market in China. However, we see plenty more potential in this country," Said Burt.

"So we're Going to Continue to Invest in China Over the Next Five Years. We See Upwards of more than 40 Million A Year in the Activities that we're doing in the china KetHyderabad Stocks. And over the next fears, it couldEasily be in the hundreds of millions, "he said.

There are some structural reaSons that make China one of the most of the most of the world. E nature of healthcare here, unmet needs and the fact that value-adddded drags are well-perceived here.

Also, China has of the most Advanced E-Health Platforms, Which Gives Amazing Opportunities to Improve Medical Care, He Said.

Ian mcaleer, general manager of Pharmanovia China, also said that the company's innology is going to follow China. " Being the no 1 Market for Pharmanovia is going to change in the foreseeable normal, "he said.

Jin Chunlin, Director of the Shanghai Municipal Health Development Research Center, Said The Aging Process in China and the Increasing Demand for Major A ND Rare Diseases Have Also Made the Market More Attractive for Innovative Drugs, Which Attracts DomStic and Foreign Pharms Alikeutical Firms Alikeutical Firms AlikeThen, then

"China's New Drug Approval and Public Medical Insurance Policies have been Inclined Truevative Pharmaceutical Companies In Recent. From 2017 to 2023, The Number of Innovative Therapies Going to the Market Has Increased Significantly, and the Rate of Innovative Drugs Included on theNational Medical Reimbursement list is increasing, "he said.

Pharmanovia Has Marketed Two Products — Both in the Bone Health Segment — In China So Far, and Plans to Roll Out Products from ITS OTHERAPEUTIC AREAS, INCLUDINGING Endocrinology, Neuropsychology, Cardiovascular and onCology, for Chinese Patients, Said Burt.

"Within the next size to 12 months, there count be another two or three products that will be effectively support China. And by 2027, we can have a right 10-P 10-P 10-P 10-P 10-P 10-P 10-P 10-P 10-P 10-P 10-P 10-P 10-P 10-P 10-P 10-P 10-P 10-P. lus Products in China with Bone Health as a Focus, "HESaid, adding that the company owns at least 25 Core Brands Globally.

Official Statistics Showed that there are design 90 Million People Suffering from Osteoporosis in China.Jaipur Investment

"But the Patients are not diagnosed and tarrated enough. If OSTEOPOROSIS is Not Treated Properly, there can be a big count to the nation aspinal frameres or Hi P fractures. The unmet Medical need is there, and we feel we can do aLOT to Help, "said build.